Eisai Study Says Obesity Drug As Good As Roche, Arena, But With Risks
This article was originally published in PharmAsia News
Executive Summary
Eisai said its Zonegran (zonisamide), first developed as an antiseizure drug, has shown in a study to be successful in reducing obesity at the same efficacy level as treatments by Roche and Arena Pharmaceuticals.